

CHAPTER ONE: INTRODUCTION.....	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
SCOPE OF REPORT	2
INTENDED AUDIENCE.....	3
METHODOLOGY AND INFORMATION SOURCES.....	4
ANALYST CREDENTIALS.....	4
RELATED REPORTS.....	4
BCC ONLINE SERVICES.....	5
DISCLAIMER	5
 CHAPTER TWO: SUMMARY.....	 6
<i>SUMMARY TABLE GLOBAL CARDIOVASCULAR FORECAST BY</i> <i>DISEASE CLASS, THROUGH 2015 (\$ MILLIONS)</i>	 6
<i>SUMMARY FIGURE GLOBAL CARDIOVASCULAR FORECAST BY</i> <i>DISEASE CLASS, 2007-2015 (\$ MILLIONS)</i>	 7
SUMMARY (CONTINUED)	8
 CHAPTER THREE: OVERVIEW	 9
CURRENT STATE OF CARDIOVASCULAR DISEASE.....	9
<i>FIGURE 1 LEADING CAUSES OF DEATH IN THE UNITED STATES;</i> <i>2006 (DEATHS PER 100,000)</i>	 9
<i>FIGURE 1 (CONTINUED)</i>	10
ESTABLISHED DRUG CLASSES IN CARDIOVASCULAR DISEASE.....	11
Statins.....	11
Angiotensin Receptor Blocker.....	11
Angiotensin Converting Enzyme (ACE) inhibitors	12
EMERGING DRUG CLASSES.....	12
P2Y12 Inhibitors and Antagonists.....	13
Factor Xa Inhibitors	13
Cholesterol-Ester Transfer Protein (CETP) Inhibitor	13
<i>TABLE 1 CETP INHIBITORS IN ACTIVE DEVELOPMENT</i>	14
KEY RECENT EVENTS IN THE CARDIOVASCULAR MARKET	14
PLAVIX METABOLIZER 2C19 TRIGGERS U.S. WARNING.....	14
VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS COMBINATION THERAPY FOR HYPERTENSION.....	 15
SUMMARY PIPELINE OF DRUGS IN DEVELOPMENT	16
<i>TABLE 2 RECENTLY APPROVED DRUGS</i>	16
<i>TABLE 3 SUMMARY PIPELINE FORECAST</i>	16
 CHAPTER FOUR: INDUSTRY STRUCTURE AND COMPETITIVE ANALYSIS.....	 17
INDUSTRY STRUCTURE	17

<i>TABLE 4 CARDIOVASCULAR MARKET SEGMENTS, SIZE, GROWTH AND SHARE, THROUGH 2010 (\$ MILLIONS)</i>	18
MARKET CONCENTRATION AND PRICE SENSITIVITY	18
<i>TABLE 5 COMPANY BY DISEASE CLASS, 2010 REVENUE (\$ MILLIONS)</i>	19
<i>TABLE 5 (CONTINUED)</i>	20
MARKET TRENDS	20
Overall Market Flat: Higher Mix of Generics Offset by Higher Volume	21
<i>TABLE 6 PATENT EXPIRATION OF CARDIOVASCULAR DRUGS (\$ MILLIONS)</i>	22
Massive Patent Expiration Is a Growth Opportunity for Generics	22
Market Expansion via Disease Prevention is the Future of Cardio Care	22
Atrial Fibrillation Is a Large and Emerging Disease State	23
Combination Therapies Are Synergistic Revenue Generators	24
Combination Therapies ... (Continued)	25
<i>TABLE 7 COMPANY BY DISEASE CLASS, 2015 REVENUE (\$ MILLIONS)</i>	26
<i>TABLE 8 MARKET SHARE BY LEADING CARDIOVASCULAR PLAYERS (\$ MILLIONS)</i>	27
<i>TABLE 9 LARGEST REVENUE GENERATING THERAPIES IN THE CARDIOVASCULAR SEGMENT, 2009 AND 2010 (\$ MILLIONS)</i>	27
CHAPTER FIVE: MARKETS BY DISEASE	28
SUMMARY OF MARKET DYNAMICS	28
<i>TABLE 10 GLOBAL CARDIOVASCULAR FORECAST BY DISEASE CLASS, THROUGH 2015 (\$ MILLIONS)</i>	29
HYPERTENSION	29
PATHOPHYSIOLOGY AND PATHOGENESIS	29
Pathophysiology and Pathogenesis (Continued)	30
<i>TABLE 11 HYPERTENSION STAGES AS MEASURED BY PRESSURE DIFFERENTIAL AT THE HEART (MMHG AND KILO-PASCAL)</i>	31
TREATMENT AND MANAGEMENT	31
<i>TABLE 12 CURRENT GLOBAL HYPERTENSION MARKET, 2007-2010 (\$ MILLIONS)</i>	32
<i>TABLE 12 (CONTINUED)</i>	33
Diovan/Co-Diovan	33
Micardis	34
Benicar	35
Norvasc	36
Cozaar/Hyzaar	36

<i>TABLE 13 GLOBAL HYPERTENSION MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	37
<i>TABLE 13 (CONTINUED)</i>	38
<i>TABLE 14 FORECAST EPIDEMIOLOGY: HYPERTENSION</i>	38
HYPERLIPIDEMIA.....	39
PATHOPHYSIOLOGY AND PATHOGENESIS.....	39
Genetic Factors in Hyperlipidemia.....	40
<i>TABLE 15 GENERAL CLASSIFICATION OF HYPERLIPIDEMIA (TRIGLYCERIDE AND TOTAL CHOLESTEROL)</i>	40
<i>TABLE 16 FREDRICKSON CLASSIFICATION OF HYPERLIPIDEMIAS</i>	41
TREATMENT AND MANAGEMENT.....	41
<i>TABLE 17 CURRENT GLOBAL HYPERLIPIDEMIA MARKET, 2007-2010 (\$ MILLIONS)</i>	41
<i>TABLE 17 (CONTINUED)</i>	42
Lipitor	42
Crestor.....	43
Crestor (Continued).....	44
Crestor (Continued).....	45
Zetia	46
Vytorin	47
Vytorin (Continued).....	48
<i>TABLE 18 GLOBAL HYPERLIPIDEMIA MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	49
<i>TABLE 19 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA</i>	49
THROMBOSIS.....	50
PATHOPHYSIOLOGY AND PATHOGENESIS.....	50
<i>TABLE 20 CURRENT GLOBAL THROMBOSIS MARKET, 2007-2010 (\$ MILLIONS)</i>	50
<i>TABLE 20 (CONTINUED)</i>	51
TREATMENT AND MANAGEMENT.....	51
Plavix	52
Lovenox	53
Lovenox (Continued).....	54
<i>TABLE 21 GLOBAL THROMBOSIS MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	55
CARDIAC FAILURE DISEASE.....	55
PATHOPHYSIOLOGY AND PATHOGENESIS.....	55
Stroke	55
<i>TABLE 22 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015</i>	56
Cardiac Arrhythmias.....	56
Angina Pectoris.....	56
Myocardial Infarction (MI).....	57
Congestive Heart Failure (CHF).....	57
Acute Coronary Syndrome (ACS)	58

<i>TABLE 23 CURRENT GLOBAL CARDIAC FAILURE MARKET, 2007-2010 (\$ MILLIONS)</i>	58
<i>TABLE 23 (CONTINUED)</i>	59
TREATMENT AND MANAGEMENT.....	59
Vastarel.....	59
Other Drugs.....	60
<i>TABLE 24 GLOBAL CARDIAC FAILURE MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	61
OTHER CARDIOVASCULAR DISEASE.....	61
PATHOPHYSIOLOGY AND PATHOGENESIS.....	61
Pulmonary Hypertension.....	61
Peripheral Artery Disease (PAD).....	62
<i>TABLE 25 OTHER CARDIOVASCULAR DISEASE CURRENT GLOBAL MARKET (\$ MILLIONS)</i>	63
TREATMENT AND MANAGEMENT.....	64
Tracleer.....	64
Other Drugs.....	65
<i>TABLE 26 OTHER CARDIOVASCULAR GLOBAL MARKET FORECAST, THROUGH 2015 (\$ MILLIONS)</i>	65
CHAPTER SIX: MARKETS BY DRUG CLASS.....	66
SUMMARY OF MARKET DYNAMICS.....	66
<i>TABLE 27 CURRENT CARDIOVASCULAR MARKET BY DRUG CLASS, 2008-2010 (\$ MILLIONS)</i>	66
SUMMARY OF MARKET DYNAMICS (CONTINUED).....	67
<i>TABLE 28 CARDIOVASCULAR MARKET FORECAST BY DRUG CLASS, THROUGH 2015 (\$ MILLIONS)</i>	68
MONOTHERAPIES.....	68
STATINS.....	68
Statins (Continued).....	69
<i>TABLE 29 STATIN CURRENT MARKET GROWTH AND SHARE, 2007-2010 (\$ MILLIONS)</i>	70
Genetic Influences to Statin Efficacy.....	70
<i>TABLE 30 STATIN DRUG DOSING AND LDL REDUCTION CORRELATION</i>	71
<i>TABLE 31 STATIN MARKET FORECAST FOR HYPER-LIPIDEMIA, THROUGH 2015 (\$ MILLIONS)</i>	71
ANGIOTENSIN RECEPTOR BLOCKER (ARB).....	72
<i>TABLE 32 COMPARISON OF ARB PHARMACOKINETICS</i>	72
<i>TABLE 33 ARB CURRENT MARKET FOR HYPERTENSION, GROWTH AND SHARE, 2007-2010 (\$ MILLIONS)</i>	73
Myocardial Infarction Risk Due to ARB Inhibition.....	73
ARB Impact on Alzheimer's Disease Risk.....	74
<i>TABLE 34 ARB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 (\$ MILLIONS)</i>	75

CALCIUM CHANNEL BLOCKERS (CCB)	75
TABLE 35 CCB CURRENT MARKET FOR HYPERTENSION, GROWTH AND SHARE, 2007-2010 (\$ MILLIONS).....	76
TABLE 36 CCB MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 (\$ MILLIONS).....	76
LOW MOLECULAR WEIGHT HEPARINS (LMWH).....	77
TABLE 37 LMWH CURRENT MARKET FOR THROMBOSIS, GROWTH AND SHARE, 2007-2010 (\$ MILLIONS).....	77
TABLE 38 LMWH MARKET FOR THROMBOSIS, FORECAST, THROUGH 2015 (\$ MILLIONS).....	78
ANGIOTENSIN CONVERTING ENZYME (ACE) INHIBITORS	78
TABLE 39 ACE INHIBITORS FOR HYPERTENSION, GOWTH AND SHARE, 2007-2010 (\$ MILLIONS).....	79
TABLE 40 ACE INHIBITOR MARKET FORECAST FOR HYPERTENSION, THROUGH 2015 (\$ MILLIONS).....	80
P2Y12 AND FACTOR XA INHIBITORS	80
Effient (Prasugrel): a Leading P2Y12 Antagonist	80
TABLE 41 P2Y12 CURRENT MARKET GROWTH AND SHARE, 2007- 2010 (\$ MILLIONS).....	81
TABLE 42 PY12 MARKET FORECAST, THROUGH 2015 (\$ MILLIONS).....	81
TABLE 43 FACTOR XA CURRENT THROMBOIS MARKET GROWTH AND SHARE, 2007-2010 (\$ MILLIONS).....	82
TABLE 44 FACTOR XA MARKET FORECAST, THROUGH 2015 (\$ MILLIONS).....	82
COMBINATION DRUG CLASSES.....	82
COMBINATION DRUG CLASSES (CONTINUED)	83
COMBINATION DRUG CLASSES (CONTINUED)	84
CHAPTER SEVEN: MARKETS BY GEOGRAPHY.....	85
SUMMARY.....	85
TABLE 45 CURRENT MARKET SIZE BY GEOGRAPHY, 2009 AND 2010 (\$ MILLIONS).....	85
METHODOLOGY.....	85
TABLE 46 MARKET FORECAST BY GEOGRAPHY, THROUGH 2015 (\$ MILLIONS).....	86
UNITED STATES	86
TABLE 47 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (U.S.)	87
TABLE 48 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (U.S.)	87
TABLE 49 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (U.S.).....	87
WESTERN EUROPE.....	87
TABLE 50 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (WESTERN EUROPE).....	88

<i>TABLE 51 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (WESTERN EUROPE)</i>	89
<i>TABLE 52 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (WESTERN EUROPE)</i>	89
JAPAN	89
<i>TABLE 53 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (JAPAN)</i>	90
<i>TABLE 54 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (JAPAN)</i>	90
<i>TABLE 55 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (JAPAN)</i>	90
STRATEGIES TO ACCESS EMERGING MARKETS	90
STRATEGIES TO ACCESS ... (CONTINUED).....	91
EMERGING MARKETS FORECAST	92
BRAZIL.....	92
MARKET OVERVIEW	92
REGULATORY CONSIDERATIONS	93
PATENT CONSIDERATIONS	93
<i>TABLE 56 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (BRAZIL)</i>	93
<i>TABLE 57 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (BRAZIL)</i>	94
<i>TABLE 58 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (BRAZIL)</i>	94
CHINA.....	94
MARKET OVERVIEW	94
REGULATORY CONSIDERATIONS	95
PATENT CONSIDERATIONS	95
<i>TABLE 59 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CHINA)</i>	96
<i>TABLE 60 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CHINA)</i>	96
<i>TABLE 61 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CHINA)</i>	97
INDIA	97
MARKET OVERVIEW	97
REGULATORY CONSIDERATIONS	97
PATENT CONSIDERATIONS	98
<i>TABLE 62 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (INDIA)</i>	98
<i>TABLE 63 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (INDIA)</i>	98
<i>TABLE 64 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (INDIA)</i>	99

RUSSIA	99
MARKET OVERVIEW	99
REGULATORY CONSIDERATIONS	99
PATENT CONSIDERATIONS	100
<i>TABLE 65 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (RUSSIA)</i>	<i>100</i>
<i>TABLE 66 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (RUSSIA)</i>	<i>100</i>
<i>TABLE 67 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (RUSSIA).....</i>	<i>101</i>
SOUTH AMERICA	101
<i>TABLE 68 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (SOUTH AMERICA)</i>	<i>101</i>
<i>TABLE 69 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (SOUTH AMERICA)</i>	<i>101</i>
<i>TABLE 70 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (SOUTH AMERICA).....</i>	<i>102</i>
CARRIBEAN	102
<i>TABLE 71 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CARRIBEAN).....</i>	<i>102</i>
<i>TABLE 72 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CARRIBEAN).....</i>	<i>102</i>
<i>TABLE 73 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CARRIBEAN).....</i>	<i>103</i>
NORTHERN EUROPE	103
<i>TABLE 74 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (NORTHERN EUROPE).....</i>	<i>103</i>
<i>TABLE 75 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (NORTHERN EUROPE).....</i>	<i>103</i>
<i>TABLE 76 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (NORTHERN EUROPE)</i>	<i>104</i>
CENTRAL AND EASTERN EUROPE	104
<i>TABLE 77 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (CENTRAL & EASTERN EUROPE).....</i>	<i>104</i>
<i>TABLE 78 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (CENTRAL & EASTERN EUROPE).....</i>	<i>104</i>
<i>TABLE 79 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015 (CENTRAL & EASTERN EUROPE).....</i>	<i>105</i>
AUSTRALIA.....	105
<i>TABLE 80 FORECAST EPIDEMIOLOGY: HYPERTENSION, THROUGH 2015 (AUSTRALIA).....</i>	<i>105</i>
<i>TABLE 81 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA, THROUGH 2015 (AUSTRALIA).....</i>	<i>105</i>

<i>TABLE 82 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015</i>	
(AUSTRALIA)	106
ASIA-OTHER	106
<i>TABLE 83 FORECAST EPIDEMIOLOGY: HYPERTENSION,</i>	
<i>THROUGH 2015 (ASIA-OTHER)</i>	106
<i>TABLE 84 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA,</i>	
<i>THROUGH 2015 (ASIA-OTHER)</i>	106
<i>TABLE 85 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015</i>	
(AUSTRALIA)	107
MIDDLE EAST	107
<i>TABLE 86 FORECAST EPIDEMIOLOGY: HYPERTENSION,</i>	
<i>THROUGH 2015 (MIDDLE EAST)</i>	107
<i>TABLE 87 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA,</i>	
<i>THROUGH 2015 (MIDDLE EAST)</i>	107
<i>TABLE 88 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015</i>	
(MIDDLE EAST)	108
SOUTHERN AFRICA	108
<i>TABLE 89 FORECAST EPIDEMIOLOGY: HYPERTENSION,</i>	
<i>THROUGH 2015 (SOUTHERN AFRICA)</i>	108
<i>TABLE 90 FORECAST EPIDEMIOLOGY: HYPERLIPIDEMIA,</i>	
<i>THROUGH 2015 (SOUTHERN AFRICA)</i>	108
<i>TABLE 91 FORECAST EPIDEMIOLOGY: STROKE, THROUGH 2015</i>	
(SOUTHERN AFRICA)	109
AFRICAN REGIONS EXCLUDED FROM EPIDEMIOLOGY	
FORECAST	109
CHAPTER EIGHT: PIPELINE ANALYSIS	110
<i>TABLE 92 APPROVED PRODUCT FORECAST, 2010 AND 2015 (\$</i>	
MILLIONS)	110
MARKET TRENDS ARISING FROM PIPELINE DEVELOPMENT	110
VALTURNA IS FIRST TO RECEIVE U.S. APPROVAL AS	
COMBINATION THERAPY FOR HYPERTENSION	111
ANTICOAGULANTS ENABLE NEW PRODUCT APPROVALS,	
IN PARTICULAR FACTOR Xa	111
P2Y12 IS A PROVEN TARGET FOR MULTIPLE	
INDICATIONS; APPROVALS ARE EXPECTED	112
APOB-100 AS A NOVEL TREATMENT FOR	
HYPERLIPIDEMIA	113
INCREASED DRIVE TO ESTABLISH AND EXTEND HIGH	
HDL CHOLESTEROL LEVELS	113
2009 APPROVALS IN CARDIOVASCULAR THERAPY	114
MULTAQ (DRONEDARONE) – SANOFI-AVENTIS	114
<i>TABLE 93 MULTAQ SNAPSHOT</i>	115
XARELTO (RIVAROXABAN) – BAYER SCHERING/J&J	116
<i>TABLE 94 XARELTO SNAPSHOT</i>	117

EFFICIENT/EFIENT (PRASUGREL) – ELI LILLY/DAIICHI SANKYO	118
<i>TABLE 95 EFFICIENT SNAPSHOT</i>	118
RENDIX (DABIGATRAN) – BOEHRINGER INGELHEIM	119
<i>TABLE 96 RENDIX SNAPSHOT</i>	120
RECENTLY FILED/PRE-REGISTRATION COMPOUNDS	121
APIXABAN – BRISTOL-MYERS SQUIBB (BMS)/PFIZER.....	121
<i>TABLE 97 APIXABAN SNAPSHOT</i>	121
BRILINTA (TICAGRELOR/AZD6140) – ASTRAZENECA	122
<i>TABLE 98 BRILINTA SNAPSHOT</i>	123
CERTRIAD (ROSUVASTATIN/ FENOFIBRIC ACID) – ASTRAZENECA/ABBOTT	124
<i>TABLE 99 CERTRIAD SNAPSHOT</i>	124
PHASE II/III COMPOUNDS.....	125
LCZ696 – NOVARTIS	125
<i>TABLE 100 LCZ696 SNAPSHOT</i>	125
EDOXABAN (DU-176B) – DAIICHI SANKYO.....	126
<i>TABLE 101 EDOXABAN (DU-176B) SNAPSHOT</i>	126
SCH 530348 – MERCK	127
<i>TABLE 102 SCH530348 SNAPSHOT</i>	127
TYRISA/DARAPLADIB – GSK	128
<i>TABLE 103 TYRISA SNAPSHOT</i>	128
BETRIXABAN – PORTOLA/MERCK	129
<i>TABLE 104 BETRIXABAN SNAPSHOT</i>	130
PIPELINE ANALYSIS BY COMPANY	131
<i>TABLE 105 PFIZER’S CARDIOVASCULAR PIPELINE</i>	131
<i>TABLE 106 SANOFI-AVENTIS’ CARDIOVASCULAR PIPELINE</i>	131
<i>TABLE 107 NOVARTIS’ CARDIOVASCULAR PIPELINE</i>	131
<i>TABLE 108 MERCK’S CARDIOVASCULAR PIPELINE</i>	132
<i>TABLE 109 BMS’ CARDIOVASCULAR PIPELINE</i>	132
<i>TABLE 110 ASTRA-ZENECA’S CARDIOVASCULAR PIPELINE</i>	132
CHAPTER NINE: COMPANY PROFILES	133
SUMMARY.....	133
<i>TABLE 111 COMPANY REVENUE AND MARKET SHARE ANALYSIS, 2007-2009 (\$ MILLIONS)</i>	133
<i>TABLE 112 MARKET FORECAST BY COMPANY, THROUGH 2015 (\$ MILLIONS)</i>	134
ABBOTT LABORATORIES.....	135
Business Overview	135
Corporate Strategy	135
ACTELION LTD.	135
Business Overview	135
Leading Products.....	136
Corporate Strategy	136

ASTELLAS PHARMA, INC.....	136
Business Overview	137
Leading Products	137
Corporate Strategy	137
ASTRAZENECA	137
Business Overview	137
Leading Products	138
Crestor	138
Atacand	138
Certriad	138
Corporate Strategy	139
BAYER AG	139
Business Overview	139
Leading Products	140
Adalat	140
BRISTOL-MYERS SQUIBB COMPANY	140
Business Overview	140
Leading Products	140
Plavix.....	140
Apixaban	141
Corporate Strategy	141
DAIICHI SANKYO, INC. (DAIICHI SANKYO GROUP).....	141
Business Overview	141
Leading Products	142
Benicar	142
Effient.....	142
Corporate Strategy	143
ELI LILLY & CO.....	143
Business Overview	143
Leading Products	143
FOREST LABORATORIES, INC.	143
Business Overview	143
Leading Products	144
Benicar	144
Corporate Strategy	144
GILEAD SCIENCES, INC.....	144
Business Overview	144
Leading Products	144
Corporate Strategy	145
GLAXOSMITHKLINE (GSK).....	145
Business Overview	145
Leading Products	145
Arixtra	145
Corporate Strategy	146

MERCK & CO., INC.....	146
Business Overview	146
Leading Products	146
Vytorin.....	146
Zetia.....	147
Cozaar.....	147
Hyzaar	148
Zocor	148
Corporate Strategy	148
MYLAN, INC.....	149
Business Overview	149
Corporate Strategy	149
NOVARTIS	150
Business Overview	150
Leading Products	150
Diovan	150
Co-Diovan.....	150
Exforge	151
Corporate Strategy	151
PFIZER, INC.	152
Business Overview	152
Leading Products	152
Lipitor.....	152
Norvasc.....	152
Revatio.....	153
Corporate Strategy	153
SANOFI AVENTIS.....	154
Business Overview	154
Leading Products	154
Plavix.....	154
Lovenox	155
Multaq	155
Corporate Strategy	156
TAKEDA PHARMACEUTICAL COMPANY LIMITED.....	156
Business Overview	156
Leading Products	157
Blopess	157
Atacand and Atacand Plus	157
Corporate Strategy	157
TEVA PHARMACEUTICAL INDUSTRIES LTD.....	158
Business Overview	158
Leading Products	158
Clopidogrel	158
Corporate Strategy	158

THE MEDICINES COMPANY, INC.....	159
Website: www.themedicinescompany.com	159
Business Overview	159
Leading Products.....	159
Angiomax.....	159
Corporate Strategy	160
UNITED THERAPEUTICS CORPORATION	160
Business Overview	160
Leading Products.....	160
Remodulin	160
Corporate Strategy	161